CN116870076A - Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof - Google Patents
Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN116870076A CN116870076A CN202311081342.6A CN202311081342A CN116870076A CN 116870076 A CN116870076 A CN 116870076A CN 202311081342 A CN202311081342 A CN 202311081342A CN 116870076 A CN116870076 A CN 116870076A
- Authority
- CN
- China
- Prior art keywords
- herba
- inflammatory
- traditional chinese
- chinese medicine
- dandelion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 27
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims description 32
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 25
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 22
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 22
- 244000146462 Centella asiatica Species 0.000 claims abstract description 20
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241000405414 Rehmannia Species 0.000 claims abstract description 19
- 229940116229 borneol Drugs 0.000 claims abstract description 19
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 19
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 244000137773 Viola philippica Species 0.000 claims abstract description 14
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 7
- 244000018795 Prunus mume Species 0.000 claims abstract description 7
- 235000011158 Prunus mume Nutrition 0.000 claims abstract description 7
- 230000017531 blood circulation Effects 0.000 claims abstract description 7
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 3
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 208000002193 Pain Diseases 0.000 claims description 43
- 230000036407 pain Effects 0.000 claims description 29
- 241000245665 Taraxacum Species 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 241000112528 Ligusticum striatum Species 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- 241000382455 Angelica sinensis Species 0.000 claims description 13
- 230000001760 anti-analgesic effect Effects 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 241000125175 Angelica Species 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 240000001949 Taraxacum officinale Species 0.000 abstract description 3
- 230000036592 analgesia Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 206010042674 Swelling Diseases 0.000 description 20
- 230000008961 swelling Effects 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- 208000000094 Chronic Pain Diseases 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 239000011505 plaster Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 6
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- 229960002390 flurbiprofen Drugs 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 201000004484 acute conjunctivitis Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229920001197 polyacetylene Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 240000006550 Lantana camara Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010052443 Myofascitis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940070818 glycyrrhizate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229930002839 ionone Natural products 0.000 description 1
- 150000002499 ionone derivatives Chemical class 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- -1 phenethyl alcohol glycoside Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses an anti-inflammatory analgesic traditional Chinese medicine composition in the technical field of traditional Chinese medicine compositions, which comprises the following components in percentage by mass: 25-35% of Japanese apricot, 10-20% of dandelion, 10-20% of viola yedoensis, 5-15% of safflower, 5-10% of angelica, 5-10% of szechuan lovage rhizome, 2-10% of prepared rehmannia root, 2-10% of centella asiatica and 1-3% of natural borneol. The scheme combines 9 traditional Chinese medicinal materials such as the herba schizophragmatis integrifolii radicis, the dandelion, the herba violae and the like, has proper compatibility of the components, synergistic effect, and has good effects of detumescence, analgesia, blood circulation promoting, blood stasis removing, anti-inflammatory, bacteriostasis and small toxic and side effects.
Description
Technical Field
The application relates to the technical field of traditional Chinese medicine compositions, in particular to an anti-inflammatory and analgesic traditional Chinese medicine composition, and a preparation method and application thereof.
Background
Chronic pain (Chronic pain) is a common Chronic disease that may be caused by a variety of causes, including tissue injury, chronic disease, psychological factors, and the like, affecting more than 30% of people worldwide. Chronic pain is different from acute pain, is a pain state which exists for a long time (generally more than 3 months), has persistent pain sensation and different degrees of pain, and has obvious influence on the psychological, emotional and life quality of patients. According to statistics, the population of chronic pain in China exceeds 3 hundred million people, and along with aging of the population and aggravation of the chronic pain, the incidence rate of the chronic pain is increased year by year, so that economic burden and medical resource pressure are brought to society. Therefore, how to effectively improve pain and improve the life quality of patients becomes a hot problem of the current research.
Currently, the main means for treating chronic pain include western medicine treatment and traditional Chinese medicine treatment. Western medicine has obvious advantages in the treatment of chronic pain, but toxic and side effects, adverse reactions, risks and drug resistance of the western medicine cannot be ignored. The traditional Chinese medicine accumulates thousands of years of medication history in the aspect of treating chronic pain, has unique curative effect and relatively small adverse reaction, and has great clinical value by deeply digging a traditional Chinese medicine compound for treating pain. In particular, with the improvement of the status of traditional Chinese medicine and the gradual prominence of the limitations of western medicine treatment, the traditional Chinese medicine has become a trend for treating chronic pain.
The application provides an anti-inflammatory and analgesic traditional Chinese medicine composition, a preparation method and application thereof, and the traditional Chinese medicine composition is prepared by firstly mixing traditional Chinese medicines such as herba hyperici japonici, dandelion, herba violae and the like, has good effects of detumescence and acesodyne, promoting blood circulation and removing blood stasis, resisting inflammation and bacteriostasis and small toxic and side effects, and provides an effective scheme for treating chronic pain.
Disclosure of Invention
The application aims to provide an anti-inflammatory and analgesic traditional Chinese medicine composition, a preparation method and application thereof, and the traditional Chinese medicine composition is prepared from the traditional Chinese medicines of herba schizophragmatis integrifolii radicis, dandelion, herba violae and the like, has proper compatibility and synergistic effect of the components, and has the good effects of detumescence and analgesia, blood circulation promoting and stasis removing, anti-inflammatory and bacteriostasis and small toxic and side effects.
In order to achieve the above purpose, the present application provides the following technical solutions:
an anti-inflammatory and analgesic traditional Chinese medicine composition comprises the following components in percentage by mass: 25-35% of Japanese apricot, 10-20% of dandelion, 10-20% of viola yedoensis, 5-15% of safflower, 5-10% of angelica, 5-10% of szechuan lovage rhizome, 2-10% of prepared rehmannia root, 2-10% of centella asiatica and 1-3% of natural borneol.
Further, the composition comprises the following components in percentage by mass: 27% of Japanese apricot, 15% of dandelion, 15% of viola philippica, 10% of centella asiatica, 10% of safflower, 8% of Chinese angelica, 8% of ligusticum wallichii, 5% of prepared rehmannia root and 2% of natural borneol.
Further, the composition comprises the following components in percentage by mass: 30% of herba schizophragmatis integrifolii radicis, 15% of dandelion, 15% of herba violae, 10% of safflower, 8% of angelica sinensis, 8% of ligusticum wallichii, 7% of prepared rehmannia root, 5% of centella asiatica and 2% of natural borneol.
Further, the composition comprises the following components in percentage by mass: 35% of herba schizophragmatis integrifolii radicis, 20% of dandelion, 20% of herba violae, 5% of safflower, 5% of angelica sinensis, 5% of ligusticum wallichii, 5% of prepared rehmannia root, 4% of centella asiatica and 1% of natural borneol.
A preparation method of an anti-inflammatory analgesic traditional Chinese medicine composition comprises the following steps:
a. selecting materials: selecting herba Hyperici Japonici, herba Taraxaci, herba Violae, carthami flos, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, radix rehmanniae Preparata, herba Centellae, and natural Borneolum Syntheticum;
b. alcohol extraction: ethanol is used for respectively carrying out ethanol extraction on the herba delphinii, the angelica sinensis, the centella asiatica, the dandelion, the viola philippica and the safflower to obtain an extracting solution, and all extracting solutions are combined to obtain an ethanol extracting solution;
c. water extraction: extracting rhizoma Ligustici Chuanxiong and radix rehmanniae Preparata with water respectively to obtain extractive solutions, and mixing all extractive solutions to obtain water extractive solution;
d. preparing paste: mixing the ethanol extractive solution and the water extractive solution, adding Borneolum Syntheticum, heating, concentrating to obtain extract, and making into Chinese medicinal composition.
Further, the concentration of ethanol in the step b when the herba hyperici japonici, the angelica sinensis, the centella asiatica, the dandelion, the viola philippica and the safflower are subjected to alcohol extraction is respectively as follows: 70-75%, 60-70%, 50-60%, 40-50%; soaking herba Gei, radix Angelicae sinensis, herba Centellae, herba Taraxaci, herba Violae and Carthami flos in ethanol, and reflux-extracting for 2-3 hr, 1-2 hr, and 20-30 min; mixing the extractive solutions, and vacuum filtering to obtain ethanol extractive solution.
And c, soaking the ligusticum wallichii and the prepared rehmannia root in distilled water, heating and reflux-extracting for 3-5 times, combining all the extracting solutions, and carrying out suction filtration to obtain a water extracting solution.
A Chinese medicinal preparation comprises a Chinese medicinal composition and pharmaceutically acceptable adjuvants.
Further, the dosage forms of the traditional Chinese medicine preparation comprise external preparations and oral preparations, wherein the external preparations comprise patches, ointments or creams, and the oral preparations comprise granules, tablets, capsules, oral liquid, medicinal granules or pills.
An application of an anti-inflammatory and analgesic Chinese medicinal composition in preparing medicines for clearing heat and detoxicating, promoting blood circulation for removing blood stasis, detumescence and relieving pain, and resisting inflammation and inhibiting bacteria is provided.
The working principle and the beneficial effects of the application are as follows: the composition has the effects of clearing heat and detoxicating, and relieving swelling and pain, and is often used for treating traumatic injury, sore throat, toothache, carbuncle swelling and muscle, pyocutaneous disease swelling and tonsillitis, pharyngolaryngitis, stomatitis, acute conjunctivitis and other diseases. The herba Hyperici Japonici contains active ingredients such as plum folic acid, herba Hyperici Japonici Mei Dusu and flavonoids, and has antibacterial, antiinflammatory, antioxidant and bone wound healing promoting effects.
Dandelion has effects of clearing heat and detoxicating, detumescence and resolving hard mass, and is often used for treating furuncle sore, stranguria due to heat, venomous snake bite, jaundice, damp-heat disease, acute conjunctivitis, etc. The modern medical research shows that the main active ingredients of dandelion comprise various functional ingredients such as flavonoid, triterpenes, sesquiterpenes, sterols, polysaccharides, organic acids, volatile oils and the like, and the dandelion has good biological activities of resisting bacteria, resisting inflammation, resisting oxidization, protecting liver, promoting urination and the like.
Herba Violae has effects of cooling blood, relieving swelling, diminishing inflammation, and relieving pain. In traditional Chinese medicine, herba Violae is often used for treating dysmenorrhea, furuncle, snake bite, traumatic injury, etc. Modern medical research shows that the herba violae contains flavonoid, volatile oil, phytosterol and other active ingredients, and has the effects of resisting inflammation, easing pain, resisting bacteria and resisting oxidation.
Safflower has the effects of activating blood, dredging channels, dispersing blood stasis and relieving pain, and has the effects of nourishing blood, activating blood and removing blood stasis with angelica, ligusticum wallichii and the like. Can be used for treating shoulder pain, arm pain, lumbago, leg pain, or pain of whole body due to obstruction of channels by qi and blood. In modern medical research, safflower contains chemical components such as flavone, alkaloid, polyacetylene, spermidine, lignan, sterol, polysaccharide and the like, and has biological activities such as dilating blood vessels, improving microcirculation, diminishing inflammation, easing pain, enhancing immune function and the like.
Dang Gui has the actions of regulating and replenishing blood, and is often used for replenishing blood, activating blood and traumatic injury. It mainly contains volatile oil, organic acid, amino acid, flavonoid, polysaccharide and other chemical components, and has the pharmacological effects of resisting inflammation, promoting hematopoiesis, protecting liver and kidney, enhancing immunity, regulating cardiac and cerebral blood vessels and the like.
Chuan Xiong is often used for treating wind-cold headache, dizziness, hypochondriac pain, abdominal pain, cold arthralgia, tendons contracture, abdominal pain, chest hypochondrium stabbing pain, traumatic injury, headache, rheumatalgia, etc. The chemical components of the ligusticum wallichii mainly comprise phthalide and dimers, alkaloids, organic acid phenol, polysaccharide and cerebroside and ceramide compounds thereof, and the ligusticum wallichii has pharmacological effects of easing pain, resisting inflammation, resisting oxidation, resisting coagulation, protecting cells and the like.
Prepared rehmannia root, radix rehmanniae Preparata has the effects of nourishing yin and blood, replenishing vital essence and marrow, and is clinically used for treating liver-kidney yin deficiency, soreness and weakness of waist and knees, bone steaming and hectic fever and the like. The prepared rehmannia root contains chemical components such as iridoid glycoside, phenethyl alcohol glycoside, ionone, amino acid, polysaccharide and the like, and has the biological activities of enhancing immunity, improving cardiovascular system, resisting inflammation, resisting fatigue and the like.
Centella asiatica has the effects of clearing heat and promoting diuresis, removing toxicity and relieving swelling, and activating blood and relieving pain, and is clinically used for treating carbuncle, sore and swelling, traumatic injury, sore throat, liver and gall stones and other diseases. Mainly contains chemical components such as triterpenoid saponins, flavonoids, volatile oils, polyacetylene olefins and the like, and has the biological activities of promoting wound healing, inhibiting scar hyperplasia, relieving arthritis, improving kidney and lung injury and the like.
Natural borneol has the advantages of fragrance, channeling, clearing heat and relieving pain, and is widely used for treating various sores and ulcers. In modern medical research, borneol has the pharmacological actions of resisting inflammation, relieving pain, resisting myocardial ischemia and the like.
The composition is prepared from the common lantana leaf, which has the functions of clearing heat and detoxicating, and relieving swelling and pain, and is used as a monarch drug; dandelion, herba violae and centella asiatica have the effects of relieving swelling and resolving masses, clearing heat and promoting diuresis, and are ministerial drugs; safflower and angelica, activating blood circulation to dissipate blood stasis; ligusticum wallichii and prepared rehmannia root have the effects of activating blood and promoting qi circulation, dispelling wind and relieving pain, and all the medicines are adjuvant medicines; borneol is used for guiding the medicine upwards, inducing resuscitation and refreshing the mind. The whole formula has the functions of clearing away heat and toxic materials, promoting blood circulation, removing obstruction in collaterals, and relieving swelling and pain.
The application provides a traditional Chinese medicine composition containing 9 traditional Chinese medicines such as herba schizophragmatis integrifolii radicis, dandelion, herba violae and the like, and a preparation prepared from the traditional Chinese medicine composition can be used for resisting inflammation and easing pain and can be used for treating chronic pain such as neck, shoulder, waist and leg pain, sprain, muscle strain, nerve pain, joint pain, musculoskeletal pain, fibromyalgia, osteoporosis, cancer pain, postoperative pain after trauma, scapulohumeral periarthritis, lumbar disc herniation, tennis elbow, myofascitis, arthritis and the like.
Based on the compatibility theory of traditional Chinese medicines, the composition takes the herba schizophragmatis integrifolii radicis as a main medicine and takes Chinese medicinal materials such as the herba violae, the dandelion, the safflower and the like as auxiliary medicines so as to achieve the effects of strengthening anti-inflammatory and analgesic effects and reducing toxic and side effects, and has the effects of treating various chronic pains such as rheumatalgia, muscle pain of bones and muscles, traumatic blood stasis and pain, joint swelling pain, neuralgia, waist, knee and the like.
The composition is prepared into clinically acceptable unused preparation types by adding auxiliary materials according to a conventional process, wherein the gel emplastrum is prepared from an extract mixture mainly comprising the herba schizophragmatis integrifolii radicis, the herba violae and the dandelion, and pharmacological experiment results show that the gel emplastrum has good anti-inflammatory and analgesic effects, so that the gel emplastrum has the beneficial effects of treating chronic pain.
Detailed Description
The following is a further detailed description of the embodiments:
the proportions of the medicinal materials of examples 1 to 3 and comparative examples 1 to 2 are shown in Table 1 below:
TABLE 1 medicinal material proportioning table
Examples 1 to 3 and comparative examples 1 to 2 were identical in terms of the preparation method except for differences in the raw materials and the proportions thereof, and the specific preparation process was as follows:
the Chinese medicinal composition shown in the embodiment 1 is prepared into the compound Dimei oral liquid-1
The stock was prepared as shown in example 1 of table 1: 300 g of local plum, 150 g of dandelion, 150 g of viola philippica, 100 g of safflower, 80 g of angelica, 80 g of ligusticum wallichii, 70 g of prepared rehmannia root, 50 g of centella asiatica and 20g of natural borneol.
The preparation method of the compound Dimei oral liquid-1 comprises the following steps:
(1) Selecting materials: 300 g of local plum, 150 g of dandelion, 150 g of viola yedoensis, 100 g of safflower, 80 g of angelica, 80 g of ligusticum wallichii, 70 g of prepared rehmannia root, 50 g of centella asiatica and 20g of natural borneol;
(2) Alcohol extraction: respectively taking 75%, 70%, 60% and 50% ethanol solution as extracting solutions, soaking herba Gei, radix Angelicae sinensis, herba Centellae, herba Taraxaci, herba Violae and Carthami flos, and performing reflux extraction for 3h, wherein reflux extraction time of herba Gei, herba Taraxaci and herba Violae is 3h, radix Angelicae sinensis and herba Centellae is 1h, carthami flos is 20min, mixing the extracting solutions, and performing suction filtration to obtain ethanol extracting solution;
(3) Water extraction: soaking rhizoma Ligustici Chuanxiong and radix rehmanniae Preparata in distilled water, reflux extracting for 3 times, mixing the extractive solutions, and vacuum filtering to obtain water extractive solution;
(4) Preparation: mixing the ethanol extractive solution obtained in step (2) with the water extractive solution obtained in step (3), adding natural Borneolum Syntheticum at a certain proportion, mixing, heating under reduced pressure to recover ethanol, concentrating, refrigerating at 5deg.C for 24 hr, and filtering to obtain medicinal liquid (compound Di Mei oral liquid-1).
The Chinese medicinal composition shown in the embodiment 2 is prepared into the compound Dimei oral liquid-2
The stock was prepared as shown in example 2 of table 1: 270 g of local plum, 150 g of dandelion, 150 g of viola yedoensis, 100 g of centella asiatica, 100 g of safflower, 80 g of angelica sinensis, 80 g of ligusticum wallichii, 50 g of prepared rehmannia root and 20g of natural borneol.
The preparation method of the compound Dimei oral liquid-2 comprises the following steps:
(1) Selecting materials: 270 g of local plum, 150 g of dandelion, 150 g of viola yedoensis, 100 g of centella asiatica, 100 g of safflower, 80 g of angelica sinensis, 80 g of ligusticum wallichii, 50 g of prepared rehmannia root and 20g of natural borneol;
(2) Alcohol extraction: respectively taking 75%, 70%, 60% and 50% ethanol solution as extracting solutions, soaking herba Gei, radix Angelicae sinensis, herba Centellae, herba Taraxaci, herba Violae and Carthami flos, and performing reflux extraction for 3h, wherein reflux extraction time of herba Gei, herba Taraxaci and herba Violae is 3h, radix Angelicae sinensis and herba Centellae is 1h, carthami flos is 20min, mixing the extracting solutions, and performing suction filtration to obtain ethanol extracting solution;
(3) Water extraction: soaking rhizoma Ligustici Chuanxiong and radix rehmanniae Preparata in distilled water, reflux extracting for 3 times, mixing the extractive solutions, and vacuum filtering to obtain water extractive solution;
(4) Preparation: mixing the ethanol extractive solution obtained in step (2) with the water extractive solution obtained in step (3), adding natural Borneolum Syntheticum at a certain proportion, mixing, heating under reduced pressure to recover ethanol, concentrating, refrigerating at 5deg.C for 24 hr, and filtering to obtain medicinal liquid (compound Di Mei oral liquid-2).
According to the preparation method, the oral liquid is prepared from comparative example 1 and comparative example 2, namely a comparative group 1 and a comparative group 2.
The Chinese medicinal composition shown in example 3 is prepared into gel plaster
The stock was prepared as shown in example 3 of table 1: 270 g of local plum, 150 g of dandelion, 150 g of viola yedoensis, 100 g of centella asiatica, 100 g of safflower, 80 g of angelica sinensis, 80 g of ligusticum wallichii, 50 g of prepared rehmannia root and 20g of natural borneol.
The preparation method of the gel plaster comprises the following steps:
(1) Selecting materials: 270 g of local plum, 150 g of dandelion, 150 g of viola yedoensis, 100 g of centella asiatica, 100 g of safflower, 80 g of angelica sinensis, 80 g of ligusticum wallichii, 50 g of prepared rehmannia root and 20g of natural borneol;
(2) Alcohol extraction: respectively taking 75%, 70%, 60% and 50% ethanol solution as extracting solutions, soaking herba Gei, radix Angelicae sinensis, herba Centellae, herba Taraxaci, herba Violae and Carthami flos, and performing reflux extraction for 3h, wherein reflux extraction time of herba Gei, herba Taraxaci and herba Violae is 3h, radix Angelicae sinensis and herba Centellae is 1h, carthami flos is 20min, mixing the extracting solutions, and performing suction filtration to obtain ethanol extracting solution;
(3) Water extraction: soaking rhizoma Ligustici Chuanxiong and radix rehmanniae Preparata in distilled water, reflux extracting for 3 times, mixing the extractive solutions, and vacuum filtering to obtain water extractive solution;
(4) Preparing paste: mixing the ethanol extract obtained in step (2) with the water extract obtained in step (3), adding natural borneol in proportion, mixing, heating and decompressing to recover ethanol, and concentrating to obtain extract;
(5) Gel matrix preparation: sodium polyacrylate and carbomer are fully swelled in water to obtain phase A. Adding aluminum glycinate and sodium polyacrylate into glycerol, stirring to obtain phase B, and dissolving tartaric acid in small amount of water to obtain phase C. Adding the phase C into the phase A, and fully and uniformly mixing to obtain the phase D.
(6) Preparation: mixing the extract obtained in step (4) with phase D in step (5) to obtain paste, mixing with phase B in step (5), uniformly coating on backing material, covering with protective film, and sealing.
Gel plaster prescription screening experiment
1. Preparation of gel patch
Sodium polyacrylate and carbomer are fully swelled in water to obtain phase A, then aluminum glycinate and sodium polyacrylate are added into glycerin, after being stirred uniformly, phase B is obtained, tartaric acid is dissolved in a small amount of water, and phase C is obtained. Adding the phase C into the phase A, and fully and uniformly mixing to obtain the phase D. Adding the liquid medicine (extract obtained in step 4 of example 3) into phase D, mixing with phase B, coating on backing, covering with protective film, and sealing.
2. Evaluation of gel patch
The amounts of other components in the fixed matrix were unchanged, the amounts of 1 component were changed, and gel patches were prepared according to the method of item 1 above (preparation of gel patches), and the application properties, uniformity, followability and film residue of the gel patches were examined with sensory evaluation as evaluation indexes, and the optimal amounts of each factor were selected.
Through a single factor test, the optimal matrix prescription is selected by taking the dosage of sodium carboxymethylcellulose (CMC-Na), tartaric acid, sodium polyacrylate and dihydroxyaluminum as factors. The sensory evaluation scoring criteria of the screening prescription are shown in Table 2, and the sensory evaluation results of the various gel matrices at different dosages are shown in Table 3.
TABLE 2 sensory evaluation scoring criteria
TABLE 3 sensory evaluation of various gel matrices at different levels
According to the method of item 1, various gel matrixes with different dosages are screened, and the results are shown in table 3, and the optimal matrix dosage of the gel plaster can be screened through the evaluation total score of a single factor experiment, wherein the optimal matrix dosage is as follows: the dosage of sodium polyacrylate is 2.00g, the dosage of sodium carboxymethylcellulose is 0.06g, the dosage of aluminum glycyrrhizate is 0.20g, and the dosage of tartaric acid is 0.05g.
Pharmacodynamic effects
(1) Influence of compound Dimei oral liquid on glacial acetic acid induced mouse torsion reaction
42 male mice of Kunming species, with a weight of 18-22 g. The dosage of each mouse is determined according to the body weight, the experimental mice are randomly divided into 7 groups which are respectively a model control group (physiological saline 0.2ml/10 g), a compound Di Mei oral liquid-1 low dose group (10 ml/kg), a compound Di Mei oral liquid-1 high dose group (20 ml/kg), a compound Di Mei oral liquid-2 low dose group (10 ml/kg), a compound Di Mei oral liquid-2 high dose group (20 ml/kg), a comparison 1 group and a comparison 2 group respectively irrigate the stomach with the traditional Chinese medicine oral liquid prepared by the comparison example 1 and the comparison example 2. The stomach was irrigated continuously for 7d, once daily. After the last administration for 1h, each group of mice was respectively injected with 0.2ml/10g of 0.6% acetic acid solution (prepared before the acetic acid solution is used), and the number of times of torsion reaction (abdominal contraction indent and extension hindlimb) of each group within 15min after the acetic acid solution injection was observed and recorded. And (3) calculating the inhibition rate of torsion reaction: percent inhibition (%) = (average number of twists of model control group-average number of twists of administration group)/average number of twists of model control group x 100%, experimental results are shown in table 4.
Table 4-influence of compound Dimei oral liquid on glacial acetic acid induced mouse torsion reaction (n=6)
Note that: in comparison with the set of models, * P＜0.001， *** p < 0.001, a represents, compared with the comparative group 1 * P is less than 0.05. As can be seen from the experimental results in Table 4, compared with the model control group, the compound Dimei oral liquid can remarkably reduce the number of times of twisting the mice caused by acetic acid, and shows remarkable analgesic activity (P < 0.001).
(2) Influence of Compound Di Mei Ning adhesive plaster on glacial acetic acid induced mouse torsion reaction
18 male mice are selected, the weight of the male mice is 18-22 g, and the male mice are randomly divided into 3 groups: blank, positive drug group (flurbiprofen gel patch) 40mg/kg, compound Di Mei Ning gel patch group (40 mg/kg,100 mg/kg). The mice were dehaired on their abdomen 1d prior to the experiment, with a range of about 2cm x 2cm size, with no skin nicks, lesions. The animals of each group were given by external application to the skin or by external application according to the designed group and dose in the morning of the next day, and then fixed with a non-irritating adhesive tape. The medicine is changed 1 time a day, and the medicine is continuously administrated for 7d. 30min after the last administration, 0.1ml/10g of glacial acetic acid with the concentration of 0.6% is injected into the abdominal cavity, the number of times of twisting the mice in 20min after the inflammation is recorded, and the inhibition rate is obtained, wherein the inhibition rate (%) = [ (number of twisting the model control group-number of twisting the administration group)/number of twisting the model control group ] x 100%. The experimental results are shown in Table 5.
Table 5 influence of compound Di Mei Ning adhesive plaster on the number of times of twisting mice by glacial acetic acid (n=6)
Note that: in comparison with the set of models, *** P＜0.001；
the results in table 5 show that compared with the blank matrix control group, the compound spot plum gel paste has 74.05% of inhibition rate on the torsion of mice caused by glacial acetic acid and 84.86% of inhibition rate on the positive drug group, and the compound spot plum gel paste has good analgesic effect on the pain of mice caused by glacial acetic acid.
(3) Influence of compound Dimei oral liquid on rat foot swelling caused by complete Freund adjuvant
SD rats are randomly divided into a control group, a model group and a compound Japanese apricot oral liquid-1 low-dose and high-dose groups (10 ml/kg and 20 ml/kg) according to the body weight, wherein each group comprises 6 Japanese apricot oral liquids. 100 μl of Complete Freund's Adjuvant (CFA) was subcutaneously injected into the plantar portion of the hind foot, and an equivalent amount of physiological saline was administered to the model control group. The intragastric administration was started on the same day, 14d was continued, and the post-lateral toe volume of the mice was measured at the same time point before the start of administration (T0) and after the administration (T7) and 14 (T14) d. The change in volume of the plantar region of the rat foot before and after the inflammation of each group of rats was calculated, and the anti-inflammatory effect of the drug was expressed as the degree of plantar swelling. Plantar swelling = plantar volume post-dose-plantar volume pre-dose.
Studies have shown that the experimental rats had significant reddening of their feet 48 hours after CFA administration. Both model and drug groups significantly increased toe volume after CFA administration compared to the normal control group (table 6); compared with the model group, the compound plum oral liquid with 7 th and 14d of continuous administration can obviously inhibit the swelling degree of the feet of rats and shows obvious anti-inflammatory activity. The experimental results are shown in Table 6.
TABLE 6 Effect of Compound Dimei oral liquid on CFA-induced rat foot swelling
Note that: in comparison with the set of models, * P＜0.05， ** p is less than 0.01; in comparison with the normal control group, ### P＜0.001。
(4) Influence of compound Dimei gel plaster on rat foot swelling caused by CFA
SD rats were randomly divided into normal control group, model control group (blank matrix gel paste), positive drug group (flurbiprofen gel paste) and compound spot Mei Ning gel paste group, 6 each. CFA 100 μl was subcutaneously injected into the plantar portion of the hind foot, and rats in the model control group were given an equivalent amount of physiological saline. Dosing was started on the same day, with continuous application of dosing for 14d, and the lateral hind toe volumes of mice were measured at the same time point before dosing (T0) and after dosing for 7 and 14 d. The change in volume of the plantar region of the rat foot before and after the inflammation of each group of rats was calculated, and the anti-inflammatory effect of the drug was expressed as the degree of plantar swelling. Plantar swelling = plantar volume post-dose-plantar volume pre-dose.
The foot volume of the rats was significantly increased after CFA administration compared to before molding. The model control and drug groups showed a significant increase in toe volume after CFA administration (table 7) compared to the normal control, and the continuously administered 7 th and 14 th days, the compound dot-matrix plum gel patch was similar to the flurbiprofen gel patch compared to the model group, which significantly reduced the swelling degree of the rat feet, showing a significant anti-inflammatory effect. CFA is widely used to induce chronic inflammatory pain models that can cause local peri-tissue inflammation and pain responses, such as foot skin and ankle pain, and the like. Based on the beneficial effects of the compound Di Mei Ning adhesive plaster on the model, the compound Di Mei Ning adhesive plaster can be used for treating related diseases such as inflammation, inflammatory pain and the like. The experimental results are shown in Table 7.
TABLE 7 Effect of Compound Dimei gel plaster on CFA-induced rat foot swelling
Note that: in comparison with the control group of the model, *** p is less than 0.001; in comparison with the normal control group, ### P＜0.001。
the application is illustrated by the above embodiments as a Chinese medicinal composition for treating traumatic injury, swelling and pain due to blood stasis, neuralgia, arthritis and other chronic pains, and its preparation method and application, but the application is not limited to the above embodiments, i.e. it is not meant that the application must be practiced by the above embodiments. It should be apparent to those skilled in the art that any modification of the present application, equivalent substitution of raw materials for the product of the present application, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present application and the scope of disclosure.
Claims (10)
1. An anti-inflammatory and analgesic traditional Chinese medicine composition is characterized by comprising the following components in percentage by mass: 25-35% of Japanese apricot, 10-20% of dandelion, 10-20% of viola yedoensis, 5-15% of safflower, 5-10% of angelica, 5-10% of szechuan lovage rhizome, 2-10% of prepared rehmannia root, 2-10% of centella asiatica and 1-3% of natural borneol.
2. The anti-inflammatory and analgesic traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in percentage by mass: 27% of Japanese apricot, 15% of dandelion, 15% of viola philippica, 10% of centella asiatica, 10% of safflower, 8% of Chinese angelica, 8% of ligusticum wallichii, 5% of prepared rehmannia root and 2% of natural borneol.
3. The anti-inflammatory and analgesic traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in percentage by mass: 30% of herba schizophragmatis integrifolii radicis, 15% of dandelion, 15% of herba violae, 10% of safflower, 8% of angelica sinensis, 8% of ligusticum wallichii, 7% of prepared rehmannia root, 5% of centella asiatica and 2% of natural borneol.
4. The anti-inflammatory and analgesic traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in percentage by mass: 35% of herba schizophragmatis integrifolii radicis, 20% of dandelion, 20% of herba violae, 5% of safflower, 5% of angelica sinensis, 5% of ligusticum wallichii, 5% of prepared rehmannia root, 4% of centella asiatica and 1% of natural borneol.
5. The method for preparing an anti-inflammatory analgesic traditional Chinese medicine composition according to any one of claims 1 to 4, comprising the following steps:
a. selecting materials: selecting herba Hyperici Japonici, herba Taraxaci, herba Violae, carthami flos, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, radix rehmanniae Preparata, herba Centellae, and natural Borneolum Syntheticum;
b. alcohol extraction: ethanol is used for respectively carrying out ethanol extraction on the herba delphinii, the angelica sinensis, the centella asiatica, the dandelion, the viola philippica and the safflower to obtain an extracting solution, and all extracting solutions are combined to obtain an ethanol extracting solution;
c. water extraction: extracting rhizoma Ligustici Chuanxiong and radix rehmanniae Preparata with water respectively to obtain extractive solutions, and mixing all extractive solutions to obtain water extractive solution;
d. preparing paste: mixing the ethanol extractive solution and the water extractive solution, adding natural Borneolum Syntheticum, heating, concentrating to obtain extract, and making into Chinese medicinal composition.
6. The method for preparing an anti-inflammatory and analgesic Chinese medicinal composition according to claim 5, wherein the concentrations of ethanol in the step b are respectively as follows: 70-75%, 60-70%, 50-60%, 40-50%; soaking herba Gei, radix Angelicae sinensis, herba Centellae, herba Taraxaci, herba Violae and Carthami flos in ethanol, and reflux-extracting for 2-3 hr, 1-2 hr, and 20-30 min; mixing the extractive solutions, and vacuum filtering to obtain ethanol extractive solution.
7. The method for preparing an anti-inflammatory and analgesic Chinese medicinal composition according to claim 6, wherein in step c, the rhizoma Chuanxiong and the radix rehmanniae Preparata are soaked in distilled water and then heated and reflux-extracted for 3-5 times, and all the extracting solutions are combined and suction-filtered to obtain the water extracting solution.
8. A Chinese medicinal preparation comprising the Chinese medicinal composition of any one of claims 1-4 and pharmaceutically acceptable excipients.
9. The traditional Chinese medicine preparation according to claim 8, wherein the external preparation comprises, but is not limited to, a patch, an ointment or a cream, and the oral preparation comprises, but is not limited to, a granule, a tablet, a capsule, an oral liquid, a granule or a pill.
10. The use of an anti-inflammatory analgesic Chinese medicinal composition according to any one of claims 1 to 4 in the preparation of a medicament for clearing heat and detoxicating, promoting blood circulation by removing blood stasis, detumescence and relieving pain, and anti-inflammatory and antibacterial.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311081342.6A CN116870076B (en) | 2023-08-25 | 2023-08-25 | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311081342.6A CN116870076B (en) | 2023-08-25 | 2023-08-25 | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116870076A true CN116870076A (en) | 2023-10-13 |
| CN116870076B CN116870076B (en) | 2024-04-09 |
Family
ID=88271701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311081342.6A Active CN116870076B (en) | 2023-08-25 | 2023-08-25 | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870076B (en) |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050074732A (en) * | 2004-01-14 | 2005-07-19 | 강명자 | Crude drug composition for treating or alleviating inflammatory disease |
| CN101278963A (en) * | 2008-05-30 | 2008-10-08 | 李念 | Liquid medicament for curing bedsore |
| WO2009117936A1 (en) * | 2008-03-25 | 2009-10-01 | 深圳力瑞医药科技有限公司 | A pharmaceutical composition with effects of antipyretic, anti-inflammatory and analgesia and its preparation method |
| CN101933991A (en) * | 2009-07-03 | 2011-01-05 | 吉林一正药业集团有限公司 | Analgesic and anti-inflammatory medicament and preparation method thereof |
| CN103393999A (en) * | 2013-08-23 | 2013-11-20 | 张凤明 | Anti-inflammatory resolutive liquid medicine for promoting blood circulation to arrest pain |
| CN105535820A (en) * | 2015-12-28 | 2016-05-04 | 内蒙古科尔沁药业有限公司 | Mongolian medicine swelling subsidence ointment |
| CN105616356A (en) * | 2014-11-07 | 2016-06-01 | 安徽中医药大学 | Peach seed-safflower Siwu granule originated from peach seed-safflower Siwu decoction, and preparation method thereof |
| CN105998435A (en) * | 2016-07-04 | 2016-10-12 | 王福宁 | Miao medicine preparation for treating osteoarticular diseases and preparation method and application thereof |
| CN106214902A (en) * | 2016-09-05 | 2016-12-14 | 佛山市顺德区宝铜金属科技有限公司 | A kind of Chinese medicine treating acute pharyngitis |
| CN106215022A (en) * | 2016-09-05 | 2016-12-14 | 佛山市顺德区宝铜金属科技有限公司 | A kind of containing Herba Androsaces Umbellatae (Herba Androsaces Coccineae) sore-throat relieving Chinese medicine and preparation method |
| CN108478638A (en) * | 2018-06-28 | 2018-09-04 | 成都春霞堂健康咨询有限公司 | A kind of external application Chinese medicine extract, preparation method and its feedstock composition for dredging mammary gland |
| CN109106811A (en) * | 2018-11-01 | 2019-01-01 | 山东省科学院生物研究所 | A kind of liquid composition of antalgic and inflammation relieving and the preparation method and application thereof |
| CN109700992A (en) * | 2019-02-27 | 2019-05-03 | 王国义 | A kind of Chinese traditional treatment new method of stomatitis |
| KR20190101632A (en) * | 2018-02-23 | 2019-09-02 | 주식회사 미싹바이오 | Anti-inflammatory composition containing medicinal herbs |
| CN110946887A (en) * | 2020-02-07 | 2020-04-03 | 山东中医药大学 | Traditional Chinese medicine extract with blood-activating anti-inflammatory effect and application thereof |
| WO2022237842A1 (en) * | 2021-05-12 | 2022-11-17 | 河北以岭医药研究院有限公司 | Pharmaceutical composition for treating rheumatoid arthritis and preparation method therefor |
-
2023
- 2023-08-25 CN CN202311081342.6A patent/CN116870076B/en active Active
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050074732A (en) * | 2004-01-14 | 2005-07-19 | 강명자 | Crude drug composition for treating or alleviating inflammatory disease |
| WO2009117936A1 (en) * | 2008-03-25 | 2009-10-01 | 深圳力瑞医药科技有限公司 | A pharmaceutical composition with effects of antipyretic, anti-inflammatory and analgesia and its preparation method |
| CN101278963A (en) * | 2008-05-30 | 2008-10-08 | 李念 | Liquid medicament for curing bedsore |
| CN101933991A (en) * | 2009-07-03 | 2011-01-05 | 吉林一正药业集团有限公司 | Analgesic and anti-inflammatory medicament and preparation method thereof |
| CN103393999A (en) * | 2013-08-23 | 2013-11-20 | 张凤明 | Anti-inflammatory resolutive liquid medicine for promoting blood circulation to arrest pain |
| CN105616356A (en) * | 2014-11-07 | 2016-06-01 | 安徽中医药大学 | Peach seed-safflower Siwu granule originated from peach seed-safflower Siwu decoction, and preparation method thereof |
| CN105535820A (en) * | 2015-12-28 | 2016-05-04 | 内蒙古科尔沁药业有限公司 | Mongolian medicine swelling subsidence ointment |
| CN105998435A (en) * | 2016-07-04 | 2016-10-12 | 王福宁 | Miao medicine preparation for treating osteoarticular diseases and preparation method and application thereof |
| CN106214902A (en) * | 2016-09-05 | 2016-12-14 | 佛山市顺德区宝铜金属科技有限公司 | A kind of Chinese medicine treating acute pharyngitis |
| CN106215022A (en) * | 2016-09-05 | 2016-12-14 | 佛山市顺德区宝铜金属科技有限公司 | A kind of containing Herba Androsaces Umbellatae (Herba Androsaces Coccineae) sore-throat relieving Chinese medicine and preparation method |
| KR20190101632A (en) * | 2018-02-23 | 2019-09-02 | 주식회사 미싹바이오 | Anti-inflammatory composition containing medicinal herbs |
| CN108478638A (en) * | 2018-06-28 | 2018-09-04 | 成都春霞堂健康咨询有限公司 | A kind of external application Chinese medicine extract, preparation method and its feedstock composition for dredging mammary gland |
| CN109106811A (en) * | 2018-11-01 | 2019-01-01 | 山东省科学院生物研究所 | A kind of liquid composition of antalgic and inflammation relieving and the preparation method and application thereof |
| CN109700992A (en) * | 2019-02-27 | 2019-05-03 | 王国义 | A kind of Chinese traditional treatment new method of stomatitis |
| CN110946887A (en) * | 2020-02-07 | 2020-04-03 | 山东中医药大学 | Traditional Chinese medicine extract with blood-activating anti-inflammatory effect and application thereof |
| WO2022237842A1 (en) * | 2021-05-12 | 2022-11-17 | 河北以岭医药研究院有限公司 | Pharmaceutical composition for treating rheumatoid arthritis and preparation method therefor |
Non-Patent Citations (8)
| Title |
|---|
| 丁艳杰;张前德;: "桃红四物汤新解", 黑龙江中医药, no. 02, 15 March 2010 (2010-03-15), pages 51 - 52 * |
| 何希瑞，等: "Anti-Nociceptive and Anti-inflammatory Activities of the Ethyl Acetate Extract of Belamcanda chinensis(L.) Redoute in Raw 264.7 Cells in vitro and Mouse Model in vivo.", J PAIN RES., 26 April 2022 (2022-04-26), pages 1221 - 1232 * |
| 夏青松;孔靖玮;李德顺;李思思;邓倩倩;李文飞;: "不同配比当归-川芎药对的抗炎、镇痛作用实验研究", 湖北中医药大学学报, no. 06, 20 December 2015 (2015-12-20), pages 1 - 4 * |
| 李效振;贾书红;张东升;孙跃博;朱晓庆;罗燕;李炳奇;谷新利;: "中药复方宫炎净的乙醇提取物抗炎作用研究", 石河子大学学报(自然科学版), no. 06, 15 December 2013 (2013-12-15), pages 688 - 692 * |
| 李艳丽;胡彦武;: "紫花地丁水提物急性毒性试验及其抗炎镇痛作用研究", 湖北农业科学, no. 02, 20 January 2013 (2013-01-20), pages 390 - 392 * |
| 杨文瑞;: "点地梅治喉痹", 中成药, no. 12, 27 December 1993 (1993-12-27), pages 46 * |
| 罗素霞;张瑞玲;: "甲氨蝶呤联合米非司酮配伍生化汤治疗植入性胎盘的疗效观察", 中国社区医师(医学专业), no. 35, 15 December 2012 (2012-12-15), pages 142 - 143 * |
| 臧浩;: "点地梅合剂治疗急性扁桃体炎咽喉炎", 江苏医药, no. 06, 29 June 1976 (1976-06-29), pages 56 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116870076B (en) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6027728A (en) | Herbal skin regeneration composition and method | |
| CN101066303B (en) | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its preparation | |
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN102228485A (en) | Composition for burn rehabilitation and preparation method thereof | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN104740425A (en) | Pharmaceutical composition for treating rheumatic arthralgia, preparation method and application of pharmaceutical composition | |
| CN101310750B (en) | External remedy for treating soft tissue injury and preparation method thereof | |
| CN116870076B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN101554449B (en) | Traditional Chinese medicine for traumatic curing | |
| CN103977367A (en) | Traditional Chinese medicament for treating qi-stagnation blood-aggregation type bedsore and preparation method thereof | |
| CN108495645A (en) | It is applied with anti-inflammation detumescence Chinese medicinal ointment | |
| CN1182866C (en) | Medicinal liquor for curing rheumatism and traumatic injuries | |
| CN110141622B (en) | Traditional Chinese medicine composition for treating pain and preparation method and application thereof | |
| CN116549522B (en) | Application of traditional Chinese medicine composition in gout | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN115120690B (en) | Traditional Chinese medicine composition for treating precocious puberty and application thereof | |
| CN112603958B (en) | Traditional Chinese medicine composition for treating myofascitis and preparation method and application thereof | |
| CN112402566B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating gonarthromeningitis | |
| CN112402565B (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method thereof | |
| CN110141621B (en) | Traditional Chinese medicine composition for treating pain and preparation method and application thereof | |
| CN101112562B (en) | Chinese traditional medicine composition for treating hyperosteogeny | |
| CN115105580A (en) | A topical Chinese medicinal composition containing nervonic acid for relieving swelling and pain, and its preparation method | |
| CN104888147A (en) | Traditional Chinese medicine ointment for shoulder periarthritis and preparation method thereof | |
| CN104606444A (en) | Traditional Chinese anesthesia medicine for tooth extraction and preparation method of traditional Chinese anesthesia medicine | |
| CN117503841A (en) | External traditional Chinese medicine for detumescence and acesodyne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |